{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:02:10Z","timestamp":1776258130526,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-025-04130-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:12:07Z","timestamp":1765887127000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan\/thiotepa for patients with central nervous system lymphomas at a single institution"],"prefix":"10.1007","volume":"123","author":[{"given":"Keiichiro","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakurako","family":"Suma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Suehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Nishikii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narushi","family":"Sugii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Obara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-8045","authenticated-orcid":false,"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"6","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","volume":"35","author":"AJM Ferreri","year":"2024","unstructured":"Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, et al. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2024;35(6):491\u2013507.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol."},{"issue":"31","key":"4130_CR2","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(31):3971\u20139.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"4130_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113436","volume":"196","author":"S Habringer","year":"2024","unstructured":"Habringer S, Demel UM, Fietz AK, Lammer F, Schroers R, Hofer S, et al. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Eur J Cancer (Oxford, England: 1990). 2024;196:113436.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"11","key":"4130_CR4","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510\u201323.","journal-title":"Lancet Haematol"},{"issue":"10","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60\u00a0years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II precis study. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37(10):823\u201333.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.bbmt.2019.01.020","volume":"25","author":"E Kondo","year":"2019","unstructured":"Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2019;25(5):899\u2013905.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"9","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403\u201310.","journal-title":"Blood"},{"issue":"3","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12185-021-03263-y","volume":"115","author":"M Nishikori","year":"2022","unstructured":"Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022;115(3):391\u20138.","journal-title":"Int J Hematol"},{"issue":"3","key":"4130_CR9","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","volume":"11","author":"E Schorb","year":"2024","unstructured":"Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024;11(3):e196\u2013205.","journal-title":"Lancet Haematol"},{"issue":"14","key":"4130_CR10","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","volume":"4","author":"E Schorb","year":"2020","unstructured":"Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378\u201381.","journal-title":"Blood Adv"},{"issue":"13","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127(13):1642\u20139.","journal-title":"Blood"},{"issue":"3","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3324\/haematol.2022.281640","volume":"108","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, et al. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica. 2023;108(3):882\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"4130_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4130_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3109\/10428194.2015.1041387","volume":"57","author":"DY Hwang","year":"2016","unstructured":"Hwang DY, Kim SJ, Cheong JW, Kim Y, Jang JE, Lee JY, et al. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. Leuk Lymphoma. 2016;57(1):51\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4130_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-019-03914-2","volume":"84","author":"E Kondo","year":"2019","unstructured":"Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, et al. Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol. 2019;84(4):849\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4130_CR16","doi-asserted-by":"publisher","first-page":"1034668","DOI":"10.3389\/fonc.2022.1034668","volume":"12","author":"J Shen","year":"2022","unstructured":"Shen J, Liu J. Bruton\u2019s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review. Front Oncol. 2022;12:1034668.","journal-title":"Front Oncol"},{"issue":"1","key":"4130_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae037","volume":"6","author":"H Yonezawa","year":"2024","unstructured":"Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, et al. Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-Oncol Adv. 2024;6(1):vdae037.","journal-title":"Neuro-Oncol Adv"},{"key":"4130_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol. 2021;11:760405.","journal-title":"Front Oncol"},{"issue":"17","key":"4130_CR19","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.7150\/jca.85756","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Zeng R, He Y, Liang L, Ou L, et al. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis. J Cancer. 2023;14(17):3182\u201390.","journal-title":"J Cancer"},{"issue":"23","key":"4130_CR20","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071\u20133.","journal-title":"Blood"},{"issue":"2","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/10428194.2018.1480771","volume":"60","author":"P Ambady","year":"2019","unstructured":"Ambady P, Szidonya L, Firkins J, James J, Johansson K, White T, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019;60(2):515\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4130_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood"},{"issue":"15","key":"4130_CR23","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139(15):2306\u201315.","journal-title":"Blood"},{"issue":"1","key":"4130_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2020","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase 1\/2 study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro-oncology. 2020;23(1):122\u201333.","journal-title":"Neuro-oncology."},{"key":"4130_CR25","volume":"17","author":"N Nakagawa","year":"2022","unstructured":"Nakagawa N, Yamano R, Kajikawa S, Kondo Y, Okumura H. Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia. Leuk Res Rep. 2022;17:100331.","journal-title":"Leuk Res Rep"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04130-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:40Z","timestamp":1776254200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04130-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04130-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research fund: Sakata-Yanagimoto Mamiko (Eisai, Bristol Myers Squib, Otuska Pharma, Chugai Pharma). The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of University of Tsukuba Hospital (approval R06-28).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Opt-out information was prominently displayed on the web page of University of Tsukuba Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}